quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:42:43·14d
INSIDERFiling
Coya Therapeutics Inc. logo

SEC Form 3 filed by new insider Pavao Mark H

COYA· Coya Therapeutics Inc.
Health Care
Original source

Companies

  • COYA
    Coya Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 9UpdateLake Street$16.00
  • Dec 4UpdateD. Boral Capital$15.00

Related

  • INSIDER14d
    SEC Form 4 filed by Pavao Mark H
  • PR15d
    Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
  • SEC22d
    SEC Form 8-K filed by Coya Therapeutics Inc.
  • PR31d
    ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
  • SEC32d
    SEC Form EFFECT filed by Coya Therapeutics Inc.
  • SEC34d
    SEC Form 424B3 filed by Coya Therapeutics Inc.
  • PR37d
    Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
  • SEC39d
    SEC Form S-3 filed by Coya Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022